about
Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET.AXL is an essential factor and therapeutic target for metastatic ovarian cancerThe association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG Oncology/Gynecologic Oncology Group trials.Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer.Concomitant chemotherapy and radiation for the treatment of advanced-stage endometrial cancer.Radiation Therapy for Recurrent Clear-Cell Cancer of the Ovary.Survival differences of Asian and Caucasian epithelial ovarian cancer patients in the United States.Utilization of and charges for robotic versus laparoscopic versus open surgery for endometrial cancer.Oral misoprostol and vaginal isosorbide mononitrate for labor induction: a randomized controlled trial.Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients.TWIST1 induces expression of discoidin domain receptor 2 to promote ovarian cancer metastasis.Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer.Obesity counseling in obstetrics and gynecology: provider perceptions and barriersInpatient management of hypercalcemia portends a poor prognosis among gynecologic oncology patients: A trigger to initiate hospice care?p5RHH nanoparticle-mediated delivery of AXL siRNA inhibits metastasis of ovarian and uterine cancer cells in mouse xenograftsDo gynecologic oncology patients with severely diminished renal function and urinary tract obstruction benefit from ureteral stenting or percutaneous nephrostomy?Type II endometrial cancers with minimal, non-invasive residual disease on final pathology: What should we do next?Gynecologic Oncologists' Perceptions of Palliative Care and Associated Barriers: A Survey of the Society of Gynecologic OncologyAssociation between body mass index and surgical menopausal symptoms in patients with early stage endometrial cancerSQ1274, a novel microtubule inhibitor, inhibits ovarian and uterine cancer cell growthCollagen Remodeling in the Hypoxic Tumor-Mesothelial Niche Promotes Ovarian Cancer MetastasisDifferences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patientsTherapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer
P50
Q34217927-B8BB238B-9642-49C1-B8B3-D05920EFF56EQ36127308-417EA788-5F4D-43A6-A626-3DD2BCCA13AFQ36172312-ED44C07B-FDA8-4E99-A472-48CCF6854432Q37620476-AA10E22B-711F-4FF2-9989-CDCB4DC271C3Q38211462-627C98E3-3DBD-4B5E-B33D-0AC777C1FDECQ38941027-78C19541-BE1B-454C-AB03-6E6325986F78Q40239588-B0E8CBA4-1215-4C7A-AD42-1C1ECBA17611Q42675453-CE439E33-D709-461F-9308-DE1452F61281Q43010294-4D77F6A5-867F-4660-929E-7FE94ED6788AQ46315816-E37CB2BC-05D4-46B9-B063-722BD7414FE7Q49952449-887CE7DA-8F88-40A0-BD92-C8EB2E8AA830Q50113702-807C2EC9-2838-4C4E-89B6-75CCF44BFEEBQ60304205-3F264965-8C6C-42F0-BA81-BAC41D732997Q61808761-EC4DCCD1-4EB2-451F-94E1-E56C90E4DB47Q64083065-FE913517-A354-4AD5-AA4A-3E5C091FD7D1Q64094479-DAEB1706-CED5-4249-B44F-AF36C97A0B30Q64894965-6A555107-99C7-4347-9F1B-B1B133C3A24FQ90898876-F5512C05-D5B0-487A-86D5-1C5FADF6925BQ91079553-FAFBB1E2-5A81-4F33-B24D-22078F717605Q91320660-1D86917D-13FA-4438-9BF9-4FE675B5EE13Q92310011-C17D0F46-D48A-4E2B-8C1A-A2D070004F86Q92958229-D97A682C-7778-4996-AF88-D7201731DA15Q93380660-E4D09844-CE99-40EE-9875-E8F112A5DA3B
P50
description
investigador
@es
researcher
@en
name
Katherine C Fuh
@en
type
label
Katherine C Fuh
@en
prefLabel
Katherine C Fuh
@en
P31
P496
0000-0002-7693-2694